Scotia Capital Inc. Novavax Inc Transaction History

Scotia Capital Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$3.76 - $6.02 $75,658 - $121,134	20,122 New	20,122 $96,000
Q1 2022 May 09, 2022	SELL	$69.73 - $142.9 $182,483 - $373,969	-2,617 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$134.56 - $217.97 $1.68 Million - $2.72 Million	-12,493 Reduced 82.68%	2,617 $374,000
Q3 2021 Nov 12, 2021	BUY	$177.8 - $270.58 $954,608 - $1.45 Million	5,369 Added 55.12%	15,110 $3.13 Million
Q2 2021 Aug 12, 2021	BUY	$121.0 - $257.67 $1.18 Million - $2.51 Million	9,741 New	9,741 $2.07 Million

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $620M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Scotia Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Scotia Capital Inc. with notifications on news.